Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn ’s Disease

ConclusionsOzanimod reduced circulating levels of all B-cell and most T-cell subsets but not monocytes or natural killer cells. Key subsets relevant to immune surveillance were not reduced, supporting the low risk of infection and malignancy with ozanimod in chronic inflammatory diseases. Levels of nonswitched memory B cells were associated with efficacy, providing a potential marker for ozanimod response.Trial Registration ClinicalTrials.gov: NCT02531113, EudraCT: 2015 –002025–19Graphical Abstract
Source: Digestive Diseases and Sciences - Category: Gastroenterology Source Type: research